AI assistant
Tvardi Therapeutics, Inc. — Director's Dealing 2021
Nov 3, 2021
9999_dirs_2021-11-03_b01c45e4-3e08-40de-b663-386db3556e37.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cara Therapeutics, Inc. (CARA)
CIK: 0001346830
Period of Report: 2021-10-29
Reporting Person: Posner Christopher (Director, Senior Advisor)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-10-29 | Common Stock | A | 5941 | $0.00 | Acquired | 22037 | Direct |
| 2021-10-29 | Common Stock | A | 142000 | $0.00 | Acquired | 164037 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-10-29 | Stock Option (Right to Buy) | $16.83 | A | 566000 | Acquired | 2031-10-29 | Common Stock (566000) | Direct |
Footnotes
F1: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to an Employment Agreement, dated October 29, 2021, between the Reporting Person and the Issuer, whereby the Reporting Person is employed as a Senior Advisor to the Issuer effective October 29, 2021 and as President and Chief Executive Officer of the Issuer effective November 9, 2021 (the "Employment Agreement"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs will vest in full on March 31, 2022, subject to the Reporting Person's continued service to the Issuer on such date.
F2: Represents the number of shares underlying RSUs granted to the Reporting Person pursuant to the Employment Agreement. Each RSU represents the contingent right to receive one share of common stock of the Issuer. 25% of the RSUs will vest on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date.
F3: 25% of the shares will vest and become exercisable on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date. These options were granted to the Reporting Person pursuant to the Employment Agreement.